文献速递性腺与生殖内分泌

88例日本先天性低促性腺激素性性腺功能减退症患者的综合分子研究

Comprehensive Molecular Studies in 88 Japanese Patients With Congenital Hypogonadotropic Hypogonadism.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该研究对88例日本先天性低促性腺激素性性腺功能减退症(CHH)患者进行基因面板分析(GPA,14个代表性致病基因)和全外显子组测序(WES,先聚焦41个致病/候选基因后扩展),提取频率<0.01的罕见变异并按 refined ACMG/AMP 标准评估致病性。54例无明确致病变异的CHH患者中寡基因频率及每人罕见变异数显著高于100例对照。结论支持CHH不仅为单基因病,也为寡基因/多因子病,并提示ZNF462、SEMA4D、CDH2变异的参与。

要点

  • 致病变异见于ANOS1、CHD7、FGFR1、PROKR2、SOX10及新发现的ZNF462。
  • 无明确致病变异的CHH患者寡基因频率及每人罕见变异数显著高于对照。

核心结论

  • CHH不仅作为单基因病发生,也作为寡基因/多因子病发生。
  • ZNF462、SEMA4D和CDH2变异可能参与CHH的发生。

研究设计与样本

  • 研究纳入88例日本CHH患者,采用基因面板分析(GPA)检测14个代表性致病基因。
  • 对58例GPA未检出明显致病变异的患者行全外显子组测序(WES),先聚焦41个致病/候选基因后扩展至其他基因。
  • 提取频率<0.01的罕见变异,采用 refined ACMG/AMP 标准评估致病性并注册至ClinVar。
  • 对照分析纳入100例对照个体,比较41个CHH相关基因中寡基因频率及每人罕见变异数。

主要发现

  • 致病变异分布于ANOS1(7例中6个变异)、CHD7(3例中3个变异)、FGFR1(15例中14个变异)、PROKR2(8例中2个变异)、SOX10(1例中1个变异)及ZNF462(1例中1个变异)。
  • 1例患者携带2个变异。
  • 在12个基因中检出潜在CHH相关变异,包括基于CHH相关分子网络推测的SEMA4D和CDH2。
  • 在41个CHH相关基因中,54例无明确致病/可能致病变异的CHH患者寡基因频率显著高于100例对照,每人罕见变异数也显著多于对照。

关键数值与推荐

  • 罕见变异定义为频率<0.01。
  • 致病性评估采用 refined ACMG/AMP 标准。
  • GPA覆盖14个代表性致病基因,WES初始聚焦41个致病/候选基因。

临床怎么用

  • 对CHH患者可先采用GPA检测14个代表性致病基因,未明者再行WES扩展检测。
  • 评估CHH遗传病因时需考虑寡基因/多因子模式,不应仅关注单基因致病变异。
  • ZNF462、SEMA4D和CDH2可作为CHH遗传检测与研究的候选基因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Congenital hypogonadotropic hypogonadism (CHH) is a genetically heterogeneous disorder, with multiple causative and candidate genes identified to date. OBJECTIVE: To clarify underlying genetic factors involved in the development of CHH. METHODS: We examined 88 Japanese patients with CHH using gene panel analysis (GPA) for 14 representative causative genes and whole-exome sequencing (WES) which was initially focused on 41 causative/candidate genes and subsequently expanded to other genes. We extracted rare variants (frequency of <0.01) and performed pathogenic assessment using refined American College of Medical Genetics and Genomics/Association for Molecular Pathology criteria and registered information in ClinVar. RESULTS: Twenty-seven pathogenic/likely pathogenic variants were identified in 30 patients through GPA performed for all 88 patients and in 4 patients through WES performed for 58 patients in whom no obvious disease-causing variants were revealed by GPA. They resided in previously known ANOS1 (6 variants in 7 patients), CHD7 (3 variants in 3 patients), FGFR1 (14 variants in 15 patients), PROKR2 (2 variants in 8 patients), and SOX10 (1 variant in 1 patient), and a hitherto unrecognized ZNF462 (1 variant in 1 patient). One patient had 2 variants. Additionally, potentially CHH-related variants were detected in 12 genes including SEMA4D and CDH2 postulated on the CHH-related molecular network. Furthermore, in the 41 CHH-related genes, the frequency of oligogenicity was significantly higher and the number of rare variants per individual was significantly larger in 54 CHH patients with no discernible pathogenic/likely pathogenic variants than in 100 control individuals. CONCLUSION: The results support the notion that CHH occurs not only as a monogenic disorder but also as an oligogenic/multifactorial disorder, and suggest the involvement of ZNF462, SEMA4D, and CDH2 variants in the development of CHH.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tanikawa W, Okamoto S, Ohara O, et al. Comprehensive Molecular Studies in 88 Japanese Patients With Congenital Hypogonadotropic Hypogonadism. J Clin Endocrinol Metab. 2026. PMID: 41042998. doi:10.1210/clinem/dgaf548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。